Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Frederick T. Murphy"'
Autor:
Dmytro Rekalov, L. Kim, Frederick T Murphy, M. Elaine Husni, Diane D. Harrison, Arthur Kavanaugh, Jocelyn H. Leu, Kim Hung Lo, Elizabeth C. Hsia
Publikováno v:
Arthritis Care & Research
Objective The present study was undertaken to evaluate the safety and efficacy of intravenous (IV) golimumab in patients with active psoriatic arthritis (PsA) through 1 year. Methods GO-VIBRANT was a phase III, randomized, placebo-controlled trial of
Publikováno v:
BMJ Case Rep
A 65-year-old woman presented to our rheumatology clinic with pain and swelling of multiple joints of her hands. After a thorough evaluation, she was diagnosed with rheumatoid arthritis and was started on hydroxychloroquine therapy. A week later, she
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::336f35a7ce8b6daa18d405b649a6e0dd
https://europepmc.org/articles/PMC6398818/
https://europepmc.org/articles/PMC6398818/
Autor:
Christine R. West, Frederick T. Murphy, Mark T. Brown, Michael D. Smith, Isabelle Davignon, David M. Radin
Publikováno v:
Arthritis & Rheumatism. 65:1795-1803
Objective To compare the efficacy of tanezumab versus placebo for reducing pain and improving physical function in patients with osteoarthritis (OA) of the hip. Methods This was a 32-week, randomized, double-blind, placebo-controlled, phase III trial
Autor:
A. Beutler, Frederick T. Murphy, Kim A. Papp, Philip J. Mease, Sudha Visvanathan, Dafna D. Gladman, Juan J. Gomez-Reino, Michael Mack, Gerald G. Krueger, Carrie Wagner, Iain B. McInnes, Michael Elashoff, Arthur Kavanaugh
Publikováno v:
Annals of the Rheumatic Diseases
Objective To determine serum biomarker associations with clinical response to golimumab treatment in patients with psoriatic arthritis (PsA). Methods GO–REVEAL was a randomised, placebo-controlled study of golimumab in patients with active PsA. Sam
Autor:
Mark T. Brown, David M. Radin, Isabelle Davignon, Christine R. West, Michael D. Smith, Frederick T. Murphy
Publikováno v:
The Journal of Pain. 13:790-798
The objective of this study was to compare the analgesic efficacy of tanezumab versus placebo in patients with osteoarthritis (OA) of the knee. This was a 32-week, randomized, double-blind, placebo-controlled phase III trial (NCT00733902). The patien
Autor:
Norman Gaylis, Jürgen Wollenhaupt, Yiying Zhou, Elizabeth C. Hsia, Josef S Smolen, Robert Landewé, Jonathan Kay, Mittie K. Doyle, Eric L. Matteson, Frederick T. Murphy
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the rheumatic diseases, 71(10), 1671-1679. BMJ Publishing Group
Annals of the rheumatic diseases, 71(10), 1671-1679. BMJ Publishing Group
Objective The aim of this study was to assess long-term golimumab therapy in patients with rheumatoid arthritis (RA) who discontinued previous tumour necrosis factor alpha (TNFα) inhibitor(s) for any reason. Methods Results through week 24 of this m
Autor:
Biao Lu, Geertrui F. Vanhove, Frederick T. Murphy, Jeffrey Tobias, John F. Peppin, Lynn R. Webster
Publikováno v:
Diabetes Research and Clinical Practice. 93:187-197
Aims To assess efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in patients with peripheral neuropathic pain. Methods This open-label, uncontrolled, 12-week study enrolled 25 patients with postherpetic neuralgia (PHN), one with HIV
Autor:
Gabriel Medrano-Ramírez, J. Morales-Torres, Ruben Burgos-Vargas, Nicholas Straniero, Elliott B. Grossbard, Ara Dikranian, Michael E. Weinblatt, Angela V. Vicente-Gonzales, Theresa K. Musser, Frederick T. Murphy, Arthur Kavanaugh
Publikováno v:
Arthritis & Rheumatism. 58:3309-3318
Objective Spleen tyrosine kinase (Syk) has been identified as an important modulator of immune signaling in B cells and cells bearing Fcγ-activating receptors. R788, a prodrug of active metabolite R406, has been shown to be an inhibitor of Syk kinas
Autor:
Seemal F Awan, Frederick T Murphy
Publikováno v:
Clinical Microbiology: Open Access.
Vector borne diseases have been associated with a number of autoimmune diseases. In this case we report a 73 year old woman initially diagnosed with lyme disease who subsequently developed guillain-barre syndrome (GBS). Her relevant clinical presenta
Publikováno v:
Journal of Arthritis.
Hemochromatosis is a metabolic disease with protean manifestations including polyarthritis. It is often under diagnosed due to poor classification criteria, ambiguity in laboratory testing and the inability to obtain a histological diagnosis. The cur